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ARTICLE
De Novo Mutations Affecting the Catalytic Ca Subunit
of PP2A, PPP2CA, Cause Syndromic Intellectual Disability
Resembling Other PP2A-Related Neurodevelopmental Disorders
Sara Reynhout,1,2,29 Sandra Jansen,3,29 Dorien Haesen,1,2 Siska van Belle,1,2 Sonja A. de Munnik,3
Ernie M.H.F. Bongers,4 Jolanda H. Schieving,5 Carlo Marcelis,4 Jeanne Amiel,6,7 Marle`ne Rio,7
Heather Mclaughlin,8 Roger Ladda,9 Susan Sell,9 Marjolein Kriek,10 Cacha M.P.C.D. Peeters-Scholte,11
Paulien A. Terhal,12 Koen L. van Gassen,12 Nienke Verbeek,12 Sonja Henry,13 Jessica Scott Schwoerer,13
Saleem Malik,14 Nicole Revencu,15 Carlos R. Ferreira,16 Ellen Macnamara,16,17 Hilde M.H. Braakman,18
Elise Brimble,19 Maura R.Z. Ruzhnikov,19,20 Matias Wagner,21,22,23 Philip Harrer,23
Dagmar Wieczorek,24,25 Alma Kuechler,25 Barak Tziperman,26 Ortal Barel,27,28 Bert B.A. de Vries,3
Christopher T. Gordon,6 Veerle Janssens,1,2,30,* and Lisenka E.L.M. Vissers3,30,*
Type 2A protein phosphatases (PP2As) are highly expressed in the brain and regulate neuronal signaling by catalyzing phospho-Ser/Thr
dephosphorylations in diverse substrates. PP2A holoenzymes comprise catalytic C-, scaffolding A-, and regulatory B-type subunits,
which determine substrate specificity and physiological function. Interestingly, de novomutations in genes encoding A- and B-type sub-
units have recently been implicated in intellectual disability (ID) and developmental delay (DD).We now report 16 individuals withmild
to profound ID and DD and a de novomutation in PPP2CA, encoding the catalytic Ca subunit. Other frequently observed features were
severe language delay (71%), hypotonia (69%), epilepsy (63%), and brain abnormalities such as ventriculomegaly and a small corpus
callosum (67%). Behavioral problems, including autism spectrum disorders, were reported in 47% of individuals, and three individuals
had a congenital heart defect. PPP2CA de novomutations included a partial gene deletion, a frameshift, three nonsense mutations, a sin-
gle amino acid duplication, a recurrent mutation, and eight non-recurrent missense mutations. Functional studies showed complete
PP2A dysfunction in four individuals with seemingly milder ID, hinting at haploinsufficiency. Ten other individuals showed muta-
tion-specific biochemical distortions, including poor expression, altered binding to the A subunit and specific B-type subunits, and
impaired phosphatase activity and C-terminal methylation. Four were suspected to have a dominant-negative mechanism, which corre-
lated with severe ID. Two missense variants affecting the same residue largely behaved as wild-type in our functional assays. Overall, we
found that pathogenic PPP2CA variants impair PP2A-B56(d) functionality, suggesting that PP2A-related neurodevelopmental disorders
constitute functionally converging ID syndromes.
Introduction
Neurodevelopmental disorders (NDDs) represent a collec-
tion of clinically heterogeneous disorders—including intel-
lectual disability (ID), epilepsy, andvarious behavioral disor-
ders—and can manifest as an isolated cognitive defect or in
combination with other comorbidities, such as congenital
abnormalities.1,2 Until recently, identifying the genetic eti-
ology ofNDDs remained challenging because of their exten-
sive clinical and genetic heterogeneity. Recent advances
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in whole-exome sequencing (WES) and whole-genome
sequencing have highlighted de novo mutations as a major
cause of ID,2–9 resulting in an increase in new clinical NDD
entities associated with ID and developmental delay (DD).1
Recently, recurrent de novo mutations in genes encoding
specific subunits of type 2A protein phosphatases (PP2As)
have been reported,3,4,10–12 establishing this phosphatase
family as a novel and important player in the etiology of ID
andDD.PP2Aenzymes catalyze dephosphorylationof phos-
pho-Ser and phospho-Thr residues in a large variety of sub-
strates, thereby counterbalancing Ser/Thr-specific protein
kinases and thus playing essential regulatory roles in cellular
signaling.13 Structurally, PP2As are holoenzymes comprising
three subunits: a catalytic C-type, a scaffolding A-type, and a
regulatory B-type subunit, the latter of which is of major
importance in determining physiological functions, sub-
strate specificity, and regulation of the complex.14–16 PP2A
complexes are encoded by 19different genes, andmutations
in three of these genes—PPP2R1A (MIM: 605983; subunit
Aa), PPP2R5C (MIM: 601645; subunit B56g), and PPP2R5D
(MIM: 601646; subunit B56d)3,4,10–12—have been conclu-
sively identified as causes of ID and DD syndromes; for
two others—PPP2R5B (MIM: 601644; subunit B56b)11 and
PPP2R2C (MIM:605997; subunitB55g)—variants in individ-
uals with ID and DD have been observed.17
So far, detailed studies on de novomutations in both genes
encoding the C subunit (PPP2CA and PPP2CB) have not
been reported. Yet, ID- and DD-related mutations in genes
involved in C subunit regulation, such as IGBP1 (MIM:
300472),18 MID1 (MIM: 300552),19 and BOD1 (MIM:
616745),20,21 have been identified. Together with muta-
tions in other PP2A subunits, these observations make the
genes encoding the C subunit themselves excellent candi-
dates for ID and DD disorders. Here, we report that de novo
mutations in PPP2CA, encoding the PP2A catalytic Ca sub-
unit, cause an ID andDD syndrome phenotypically charac-
terized by mild to severe ID and DD, behavioral problems,
variable types of epilepsy, hypotonia, and structural brain
abnormalities. In addition, we provide functional evidence
for a mutation-specific pathophysiological mechanism
resulting in at least a common impairment of PP2A-B56d
holoenzyme functionality. Our data further highlight the
importance of PP2A function in neurodevelopment.
Material and Methods
Generation of PPP2CA Mutants
To study the functional consequences of de novo missense muta-
tions, we cloned the coding region of wild-type (WT) Ca cDNA
into an N-terminally HA-tagged eukaryotic expression vector
(pMB001) by using XbaI and BamHI sites. Mutated Ca constructs
were directly generated from this pMB001 vector through PCR-
based site-directed mutagenesis (Stratagene) with proofreading
Pwo polymerase (Roche Applied Science) and complementary
DNA oligonucleotide primers (Sigma Genosys) containing the
desired point mutations (primer sequences in Table S1). To
generate the Ca p.Phe308dup variant, we directly incorporated
the mutation into the reverse Ca stop primer. We cloned the cod-
ing region, PCR-amplified with a Ca start primer and this mutated
stop primer (primer sequences in Table S1), into pMB001 by using
XbaI and BamHI restriction sites. All mutations were confirmed by
sequencing (LGC Genomics).
Cellular PP2A Binding Assays
HEK293T cells were transfected with PEI transfection reagent
according to a standard protocol. 48 hr after transfection, cells
were rinsed with PBS, lysed in 200 mL NET buffer (50 mM
Tris HCl [pH 7.4], 150 mM NaCl, 15 mM EDTA, and 1%
Nonidet P-40) containing protease and a phosphatase inhibitor
cocktail (Roche Applied Science), and centrifuged for 15 min at
13,000 3 g. If the experiment required measuring of phosphatase
activity, TBS was used instead of PBS, and phosphatase inhibitors
were omitted from the lysis buffer.
For pull-down experiments, cell lysates were incubated at 4C
for 1 hr with 500 mL NENT100 buffer (20 mM Tris HCl [pH 7.4],
1 mM EDTA, 0.1% Nonidet P-40, 25% glycerol, and 100 mM
NaCl) containing 1 mg/mL bovine serum albumin (BSA) and
30 mL monoclonal anti-HA-Agarose antibody beads (Sigma-
Aldrich; for HA pull-down), 30 mL glutathione-Sepharose beads
(GE Healthcare; for GST pull-down), or 30 mL GFP-trap-A beads
(ChromoTek; for GFP trapping) on a rotating wheel. The beads
were washed twice with 0.5 mL NENT100 containing 1 mg/mL
BSA and twice with 0.5 mL NENT300 containing 300 mM NaCl.
In all cases, bound proteins were eluted by the addition of
23NuPage sample buffer (Invitrogen) and boiling. The eluted pro-
teins were subsequently analyzed by SDS-PAGE on 4%–12% (w/v)
Bis-Tris gels (Bio-Rad) and immunoblotting. The membranes were
blocked in 5%milk solution in TBS and 0.1% Tween-20 for 1 hr at
room temperature (RT) and subsequently incubated with the
primary antibody overnight at 4C. The following primary mouse
antibodies were used: anti-HA (Sigma-Aldrich), anti-GST (Sigma-
Aldrich), anti-GFP (generously supplied by Dr. P. Parker at the
Francis Crick Institute, London, UK), anti-PP2A-A subunit (gener-
ously supplied byDr. S. Dilworth atMiddlesexUniversity, London,
UK), anti-demethyl-PP2A clone 1D7 (BioLegend), anti-FLAG M2
(Sigma-Aldrich), anti-vinculin (Sigma-Aldrich), and anti-alpha4
clone 5F6 (Millipore).
After being washed in TBS and 0.1% Tween-20, the membranes
were incubated at RT for 1 hr with horseradish-peroxidase-conju-
gated secondary antibodies (Dako) and developed on an Image-
Quant LAS 4000 system (GE Healthcare) with a WesternBright
ECL detection kit (Advansta). All densitometric quantifications
were done with ImageJ software.
HA Peptide Elution
For binding experiments with the HA-tagged p.Arg214* Ca
mutant, anti-HA-agarose-bound proteins were eluted for 30 min
at 4C after the final washing step by the addition of HA peptide
(Sigma-Aldrich) at 200 ng/mL. The remaining beads were spun
down, and the eluate was transferred for further use.
PP2A Activity Assays
After HA pull-down, beads were washed once more with 20 mM
Tris HCl (pH 7.4) and 1 mM DTT (Tris-DTT) and finally resus-
pended in 80 mL Tris-DTT solution. All assays were performed
with 20 mL of this ‘‘phosphatase suspension’’ and 9 mL of 2 mM
stock of K-R-pT-I-R-R phosphopeptide for 20–40 min at 30C (still
in the linear range of the assay). The released free phosphate was
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determined by the addition of BIOMOL Green (catalog no. BML-
AK111-0250, Enzo). After 20 min of incubation at RT, absorbance
at 620 nm was measured in a multi-channel spectrophotometer.
We subsequently obtained specific phosphatase activity by cor-
recting the measured absorbance for the input of HA-tagged Ca,
as determined by immunoblotting with anti-HA antibodies and
signal quantification by ImageJ.
Statistics
Statistical analysis of biochemical data was assessed with one-
sample Student’s t tests in which the data were compared with
WT values that were set at 100% in each experimental replicate.
p values below 0.05 were considered significant.
Results
Clinical Spectrum Associated with PPP2CA Mutations
Through international collaboration,2,22 we recruited 16
individuals with a de novo mutation in PPP2CA (Figures
1A and 1B). This study was approved by the local institutes
under the realm of diagnostic testing. Detailed clinical in-
formation is provided in the Supplemental Note and sum-
marized in Table 1. Individuals were 1.5–23 years old and
had mild to profound ID and DD, and ten had severe lan-
guage impairment that was worse than expected in several
individuals given their level of development. Behavioral
problems, of which autism spectrum disorders (ASDs)
were most frequently diagnosed, were noted in 7 of 15 in-
dividuals (47%). One individual (individual 7) also had
psychotic episodes after which she had progressive cogni-
tive dysfunction and worsening behavioral problems.
Regression of development was also noted in individual
3. Ten individuals (63%) had seizures, albeit in different
forms: two showed fever-related seizures, one was diag-
nosed with epileptic encephalopathy, two had focal sei-
zures (one of whom was diagnosed with focal electrical
status epilepticus during sleep), two had generalized
tonic-clonic seizures, one was diagnosed with Jeavons
syndrome, one had hypsarrhythmia, and one had an un-
known type of seizures. Brain imaging was performed in
15 individuals and showed dilated ventricles (4/15),
delayed myelination (2/15), and dysplasia or absence of
the corpus callosum (4/15). Two individuals had macroce-
phaly, one of whom was also tall, and five individuals had
A
  
C 
Individual 3  
p.(Phe146Leufs*29) 
Individual 8  
p.(Gln125*) 
Individual 2 
p.(Arg295*) 
Individual 12  
p.(Asp131His) 
Individual 14  
p.(Asp88Gly) 
B
Figure 1. Schematic Overview of the PP2A Complex, Variants in the PP2A Catalytic Ca Subunit, and Photographs of Individuals
(A) Overview of the PP2A complex based on the canonical subunits. Gene names encoding the subunit components are listed in each
subunit. PPP2CA encodes the catalytic subunit alpha, highlighted in green. Subunits known for their involvement in ID and DD are
annotated with an asterisk.
(B)De novomutations identified in individuals with ID and DD are shownwith respect to their exonic and Ca protein localization; exon
notation is indicated in the ribbon protein structure. The C-tail sequence involved in carboxymethylation and phosphorylation is
enlarged for visualization purposes. Note that the partial deletion is not depicted.
(C) Facial features of individuals with a de novomutation in PPP2CA. Some individuals had mild dysmorphisms, but a consistent facial
gestalt was not observed. Informed consent was provided by the parents.
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Table 1. Main Clinical Features of Individuals
General
Information Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7 Individual 8
Age 6 y 7 y 13 y 3 y, 10 m 19 y 2 y, 4 m 23 y 2 y, 1 m
Gender male female male male female female female Female
Chr change
(hg19)
g.133536680T>C g.133533511dup g.133537587del g.133533469_
133533471dup
g.133536124G>A g.133536680T>C g.133536096T>A g.133537652G>A
GenBank:
NM_002715.2
c.572A>G c.882dup c.438del c.922_924dup c.640 C>T c.572A>G c.668A>T c.373C>T
Protein
change
p.His191Arg p.Arg295* p.Phe146Leufs*29 p.Phe308dup p.Arg214* p.His191Arg p.Asp223Val p.Gln125*
Mutation
type
missense nonsense frameshift 1 amino acid
insertion
nonsense missense missense nonsense
Inheritance de novo de novo de novo de novo de novo de novo de novo de novo
Other
variants?a
 þ   þ  þ þ
Proposed
mechanism
haploinsufficiency
of PP2A-B56d
complexes
dominant-negative
effect on PP2A-B56d
complexes
haploinsufficiency:
null allele (no
expression)
dominant-
negative effect
on all PP2A-B56
complexes
haploinsufficiency:
null allele (latent
complex with
alpha 4)
haploinsufficiency
of PP2A-B56d
complexes
unclear haploinsufficiency:
null allele
(no expression)
Growth
Height þ2 SD þ2.5 SD þ1.3 SD þ1.7 SD 0.2 SD 0 SD þ0.7 SD 1.3 SD
Head
circumference
þ2.5 SD þ0.5 SD 1.5 SD 3.9 SD NK 0.2 SD þ2.8 SD 0.8 SD
Weight 0.2 SD 0 SD 1.1 SD þ0.7 SD >þ2.5 SD NK NK 0.6 SD
Neurological
DD and ID
(degree)
þ (mild) þ (severe) þ (mild) þ (moderate) þ (mild to
moderate)
þ (mild) þ (mild) þ (mild)
Severe
language
delay
þ þ þ þ þ NK  
Regression   þ    þ (after period
with psychoses)

Behavioral
problems
 þ (automutilation,
stereotypic behavior)
þ (PDD-NOS)  þ (ASD, ADHD) NK þ (ASD,
psychoses)

Hypotonia  þ þ  þ  þ (mild) þ
Epilepsy
(type)
þ (related to fever) þ (tonic-clonic
seizures, absences)
þ (focal left
temporal, mostly
at night)
 þ (generalized
tonic-clonic
seizures, absences)
þ (related to
fever, tonic-clonic
seizures)
 
Epilepsy
syndrome
NA epileptic
encephalopathy
focal ESES NA Jeavons syndrome NA NA NA
Age of onset 11 m 6 m 10 y NA 6 y NK NA NA
Age of offset 18 m ongoing ongoing NA ongoing NK NA NA
Brain
abnormalities
þ (ventriculomegaly) þ (ventriculomegaly,
gracile corpus
callosum, delayed
myelinization)
 þ (posterior
hypoplasia of
corpus callosum,
unmyelinated
left temporal
lobe, nonspecific
periventricular
white-matter
hyperintensities)
 þ (mildly
underdeveloped
pons,
mesencephalon,
mild dilated
lateral and third
ventricles)
 þ (reduced white
matter
[supratentorial
and infratentorial],
some global
atrophy of the
brain [pons and
corpus callosum],
bilateral plexus
choroideus cysts)
Other  sleeping difficulties   burning pain from
neck down to
left leg
  broad-based gait
(Continued on next page)
142 The American Journal of Human Genetics 104, 139–156, January 3, 2019
Individual 9 Individual 10 Individual 11 Individual 12 Individual 13 Individual 14 Individual 15 Individual 16
Total
(Percentage)
1 y, 9 m 8 y 2 y, 4 m 11 y 12 m 4 y 3 y, 4 m 7 y NA
male female male male male female male male 9 males, 7 females
g.133537645T>C g.133534840T>C deletion at
chr5: 133,
546,961–
133,667,321
g.133537634C>G g.133537659C>G g.133541662T>C g.133541746C>A g.133536097C>G NA
c.380A>G c.794A>G NA c.391G>C c.366G>C c.263A>G c.179G>T c.667G>C NA
p.Tyr127Cys p.Tyr265Cys NA p.Asp131His p.Gln122His p.Asp88Gly p.Gly60Val p.Asp223His NA
missense missense partial
deletion
missense missense missense missense missense NA
de novo de novo de novo de novo de novo de novo de novo de novo NA
  þ  þ    NA
haploinsufficiency
of PP2A-B56
and PR72
complexes;
dominant-
negative effect
on PP2A-B55
and PP2A-STRN
complexes
haploinsufficiency:
significant
impairment of
any trimer
formation
haploinsufficiency
(deletion)
haploinsufficiency
of PP2A-B56
complexes
haploinsufficiency? dominant-
negative
effect on
PP2A-B56g
and B56d
complexes
haploinsufficiency:
poor expression
unclear NA
þ0.4 SD 2 SD 3 SD 1.6 SD 1.9 SD 0.8 SD 0 SD 2 SD NA
3 SD 2.3 SD 3 SD 1.1 SD 4.6 SD <2 SD þ1.2 SD 0 SD NA
0.2 SD 1.5 SD 2 SD 2.1 SD 1.9 SD 0.6 2 SD 1.5 SD NA
þ (severe) þ (mild) þ (mild) þ (profound) þ (moderate) þ (severe) þ (mild) þ (severe) 16/16 (100%)
þ þ  þ NA þ  þ 10/14 (71%)
        2/16 (13%)
 þ (ASD, ADHD)     þ þ (ASD) 7/15 (47%)
þ þ  þ þ þ  þ (mild) 11/16 (69%)
 þ (NK)  þ (staring spells,
head drops,
and tonic-clonic
seizures)
þ (focal epilepsy
with secondary
generalization)
þ (generalized
tonic-clonic
seizures)
 þ (generalized
tonic-clonic
seizures)
10/16 (63%)
NA NK NA hypsarrhythmia
(West syndrome)
not specified not specified NA not specified NA
NA 3 y NA 8 m 5 m 1 w NA 1 y NA
NA ongoing NA ongoing ongoing ongoing NA ongoing NA
þ (pontocerebellar
hypoplasia,
mild
ventriculomegaly)
þ (nonspecific
thinning of
the corpus
callosum,
mild volume
loss of the
cerebellum)
NK  þ (microcephaly,
enlarged
subarachnoid
spaces,
nonspecific
findings of
cerebral
underdevelopment)
þ (slightly
dilated external
and internal
subarachnoid
spaces, diffuse
but discrete
atrophy,
adequate
myelination)
 þ (bilateral
dilatation of
perivascular
spaces along
the corona
radiata)
10/15 (67%)
optic-nerve
anomaly
NK  choreiform
movements
 stereotypic
movements
  6/15 (40%)
(Continued on next page)
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microcephaly. A recognizable facial gestalt could not be
observed, but some individuals showed mild dysmorphic
features, such as a full nasal tip and megalocornea, and
one individual had an asymmetrical face (Figure 1C).
Other clinical observations included hypotonia (11/16
[69%]), feeding difficulties (9/15 [60%]), vision problems
(6/14 [43%]), and congenital heart defects, the last of
which included a muscular ventricular septal defect, atrial
septal defect, and trileaflet aortic valve in three separate
individuals.
Mutational Spectrum Is Diverse and Suggests Loss of
PPP2CA Subunit Functioning
In total, 15 different de novo mutations in 16 individuals
were identified through routine clinical diagnostic proced-
ures, includingWES (15 individuals) and microarray-based
copy-number analysis (one individual; Figure 1B). The
latter detected a 120 kb deletion (chr5: 133,546,961–
133,667,321; GRCh37) including PPP2CA exon 1 and the
30 coding region of CDKL3 in individual 11. The variants
identified byWES included a recurrent missense mutation,
c.572A>G (p.His191Arg) (which is predicted to be delete-
rious by MutationTaster23 and affects a highly conserved
nucleotide and amino acid position in the ‘‘loop switch’’
of PP2A-C24) in individuals 1 and 6. The conformation of
the loop switch determines the conformation of the active
site and the binding of catalytic metal ions.24 In addition,
His191 is one of four residues forming a hydrophobic
cage accommodating binding of pharmacologic PP2A in-
hibitors, such as okadaic acid and microcystin.25 Gln122
Table 1. Continued
General
Information Individual 1 Individual 2 Individual 3 Individual 4 Individual 5 Individual 6 Individual 7 Individual 8
Facial
Eyes hypertelorism,
prominent eyes
 periorbital fullness
restricted to upper
eyelids, long
eyelashes
ptosis, short
palpebral
fissures
 prominent eyes,
epicanthic folds
small palpebral
fissures, deep-set
eyes
megalocornea
Nose full nasal tip,
low-hanging
columella
broad nasal bridge full nasal tip broad nasal tip   broad nasal tip asymmetrical
nostrils and
bifid nasal tip
Philtrum short philtrum short philtrum  short philtrum    
Other
dysmorphic
features
broad forehead,
frontal bossing,
square shape of
both ears
open fontanel,
plagiocephaly, some
frontal bossing,
prominent upper
lip, sacral dimple
 trigonocephaly,
double hair
whorl, high
palate, low-set
and anteverted
ears, retrognatia
crowded teeth plagiocephaly broad forehead,
freckling around
the mouth
plagiocephaly
Other
Extremities single left palmar
crease, long fingers
and toes, bilateral
sandal gap
bilateral fetal finger
pads, single left
palmar crease
 poorly developed
flexure fold on the
third right finger,
incomplete single
transverse palmar
crease, adducted
thumbs (reducible);
X-ray: ovoid
appearance of
vertebrae, coxa
valga, slender
distal phalanges
hypermobile knees mild shortened
fifth digits
 hyperlaxity
Feeding
difficulties
þ þ þ     
Vision
problems
    periods of sudden
vision loss and
pain in left eye
megalocornea,
moderated
excavated
papillae, mild
hypermetropia
(both eyes þ2)
NK megalocornea,
strabismus
Other 4 cafe´-au-lait spots
(max 5 mm)
 vitamin B12
deficiency
elevated right
diaphragm
recurrent ear
and urinary-tract
infections, heart
murmur, fractures
after minimal
trauma
diastasis recti frequent airway
infections as a
child
muscular
ventricular
septal defect
Abbreviations are as follows: þ, present; , not present; w, weeks; y, years; m, months; NK, not known; NA, not applicable; SD, standard deviation; DD, devel-
opmental delay; ID, intellectual disability; PDD-NOS, pervasive developmental disorder not otherwise specified; ASD, autism spectrum disorder; ADHD, attention
deficit hyperactivity disorder; ESES, electrical status epilepticus during sleep; CVI, cerebral visual impairment.
aAdditional information on variant(s) in other gene(s) is in the Supplemental Note.
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is another of those four residues25 and was identified to be
substituted into a histidine in individual 13 (p.Gln122His).
Two other missense mutations, c.380A>G (p.Tyr127Cys)
and c.794A>G (p.Tyr265Cys), affect two tyrosine residues
that are within the active site and are involved in direct
contacts with okadaic acid and microcystin (Tyr265)25
and with major PP2A cellular activators, such as PTPA
(Tyr127 and Tyr265)26 and the PP2A methyltransferase
LCMT-1 (Tyr127).27 The c.391G>C (p.Asp131His) variant
harbors a charge reversal in an amino acid residing nearby
the ‘‘helix switch’’ that is directly involved in binding
to LCMT-127 and the PP2A inhibitor TIPRL1.28 The
c.179G>T (p.Gly60Val) and c.263A>G (p.Asp88Gly) vari-
ants are in close proximity to amino acids Asp57, His59,
and Asp85, which are directly involved in the binding of
catalytic metal ions in the active site of PP2A-C.25
Moreover, His59 is involved in direct binding to okadaic
acid and microcystin,25 LCMT-1,27 and PTPA.26 The two
remaining missense variants, 667G>C (p.Asp223His) and
c.668A>T (p.Asp223Val), affect an amino acid of unknown
functional significance.
If not degraded by nonsense-mediated RNA decay,
the frameshift c.438del (p.Phe146Leufs*29) and two
of the nonsense mutations, c.373C>T (p.Gln125*) and
c.640C>T (p.Arg214*), are predicted to result in severely
C-terminally truncated proteins. The remaining nonsense
mutation c.882dup (p.Arg295*) is located in the ultimate
exon and is predicted to result in a small, 14 amino acid
truncation of the Ca C-terminal tail. Importantly, this
highly conserved C tail represents a focal point of PP2A
regulation29 and is reversibly modified by phosphoryla-
tion30 and carboxymethylation31–34 within the six most
Individual 9 Individual 10 Individual 11 Individual 12 Individual 13 Individual 14 Individual 15 Individual 16
Total
(Percentage)
bilateral
epicanthal
folds
 periorbital
fulness,
upslanting
palpebral
fissures
  almond-
shaped eyes
  NA
      broad nasal
tip, small
alae nasi
 NA
        NA
prominent
metopic
suture, mild
micrognathia
 full cheeks,
thin upper
lip, everted lower
lip, square
configuration
of the lobule
of the ear
(right bigger
than left)
high arched
palate
 small mouth,
high palate
  NA
bridged palmar
crease,
bilateral
ulnar
deviation of
wrists and
fingers,
partially
adducted
thumbs, right
hand greater
than left
NK bilateral
fifth-finger
clinodactyly
hyperlaxity bilateral single
palmar crease,
bilateral
adducted
thumb
atypical single
left palmar
crease, pes
planus,
overlapping
toes
single left
palmar crease
 NA
þ NK þ þ þ þ þ (infancy)  9/15 (60%)
CVI NK immature
retina at
the age
of 1 m
does not
track or
blink to
threat
    6/14 (43%)
mild bilateral
sensorineural
hearing loss
NK inguinal
hernia,
umbilical
hernia
constipation,
atrial septal
defect, low
bone mineral
density
trileaflet aortic
valve, multiple
cafe´-au-lait
macules
 sacral
haemangioma
 NA
The American Journal of Human Genetics 104, 139–156, January 3, 2019 145
C-terminal residues (304-T-P-D-Y-F-L-309), affecting PP2A
holoenzyme assembly and activity (Figure 1B).35–37 Inter-
estingly, individual 4 harbors a duplication of the
phenylalanine in this sequence (T-P-D-Y-F-F-L), rendering
the C-tail 1 amino acid longer and possibly hindering
PP2A assembly and/or activation (Figure 1B).
Population metrics based on large databases (such as the
Exome Aggregation Consortium [ExAC]) Browser) indicate
that, after sequence context andmutability are considered,
PPP2CA is depleted of loss-of-function (LoF) variants ac-
cording to multiple LoF metrics (pLI ¼ 0.99; Z score ¼
4.47). Whereas these population signatures cannot be
considered evidence of causality on their own, they
support a hypothesis that PPP2CA variants leading to a
functional loss are under strong purifying selection in
the human population and that their occurrence could
contribute to clinical phenotypes.
Both Haploinsufficiency and Non-haploinsufficiency
Mechanisms Might Underlie the ID and DD Syndrome
Caused by De Novo Variants in PPP2CA
We next set out to analyze both the catalytic capacity and
the subunit binding of the de novo mutations affecting
PPP2CA. We first attempted to determine protein levels
of 14 different de novo mutants (one frameshift, three
nonsense, one in-frame duplication, and nine missense
mutants) in HEK293T cells, a frequently used model for
PP2A biochemistry studies. We co-expressed the N-termi-
nally HA-tagged Camutants with GFP to control for trans-
fection efficiency. Anti-HA immunoblotting using total
protein lysates of the transfected cells consistently showed
the presence of protein for 12 of 14 constructs (Figure 2);
that is, despite the clear presence of GFP in all conditions
tested, the p.Gln125* and p.Phe146Leufs*29 mutants
failed detection (Figure 2), suggesting that these mutants
might not be stable. Thus, we concluded that for the
p.Gln125* and p.Phe146Leufs*29 variants, haploinsuffi-
ciency is the likely underlying pathophysiological mecha-
nism. In addition, a persistent lower protein level was seen
for p.Gly60Val, leading to an inefficacy in generating
reliable biochemical data. This could imply that this
mutant is not stable, prompting us to advocate for a hap-
loinsufficient mechanism in this case as well. Given the
clear protein levels of all other variants examined, a domi-
nant mechanism remained possible, and we further inves-
tigated this in additional functional assays.
PPP2CA Mutations Severely Compromise Phosphatase
Activity in Most Cases
To determine intrinsic catalytic activity of the 11 Ca
mutants that resulted in stable protein levels, we isolated
the proteins from total lysates of transfected HEK293Tcells
by pull-down on HA-agarose beads and washed and incu-
bated them with a short phospho-peptide (K-R-pT-I-R-R)
for varying times (20–40 min) at 30C, after which we
used BIOMOL Green to measure the release of free phos-
phate. An inactive Ca mutant (p.Asp85Asn) was included
as a negative control.34 Whereas essentially no phospha-
tase activity was found for p.Asp85Asn, the activity of
p.Gln122His, p.His191Arg, p.Asp223His, and p.Arg295*
was severely decreased to 30%–50% of WT activity
(Figure 3 and Table 2). In addition, PP2A activity was virtu-
ally absent for the p.Asp88Gly, p.Tyr127Cys, p.Arg214*,
p.Tyr265Cys, and p.Phe308dup mutants (Figure 3).
Together with the absence of the p.Gln125* and p.Phe146
Leufs*29 variants and the low levels of p.Gly60Val, these
results further suggest that the underlying pathophysio-
logical mechanism is a functional loss.
On the other hand, p.Asp131His and p.Asp223Val vari-
ants displayed similar or even higher activity, indicating
a divergent mechanism in these cases.
Carboxymethylation Assay Further Suggests PP2A
Functional Defects
To further underscore the above activity data, we addressed
potential changes in carboxymethylation of the Ca
mutants by using commercially available demethyl-spe-
cific antibodies. It has previously been demonstrated that
Figure 2. Levels of Mutant PP2A Ca Subunits in HEK293T Cells
HA-tagged WT and mutant Ca proteins were co-expressed with GFP (transfection control) in HEK293T cells. Protein levels were
monitored in total protein lysates by immunoblotting with anti-HA and anti-GFP antibodies. Vinculin was used as a loading control.
Abbreviated amino acid changes are as follows: H191R, p.His191Arg; R295*, p.Arg295*; F308dup, p.Phe308dup; R214*, p.Arg214*;
F146fs, p.Phe146fs; Q125*, p.Gln125*; Y127C, p.Tyr127Cys; D131H, p.Asp131His; D223V, p.Asp223Val; Y265C, p.Tyr265Cys; G60V,
p.Gly60Val; D88G, p.Asp88Gly; Q122H, p.Gln122His; and D223H, p.Asp223His.
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loss of the single C-terminal Leu309 residue is already suf-
ficient to prevent methylation.27,35 Hence, it is reasonable
to predict that methylation of the truncated p.Arg214*
and p.Arg295* mutants is no longer possible. In con-
trast, predicting a potential methylation defect of the
p.Asp88Gly, p.Gln122His, p.Tyr127Cys, p.Asp131His,
p.His191Arg, p.Asp223His, p.Asp223Val, p.Tyr265Cys,
and p.Phe308dup mutants is more difficult. We therefore
introduced the latter mutants, as well as WT Ca and
the p.Arg295* mutant, as HA-tagged fusion proteins and
subsequently assessed their methylation status in HA
pull-downs.
Anti-demethyl immunoblots indicated that the
p. Asp88Gly, p.Gln122His, p.Tyr127Cys, p.Asp223Val,
and p.Tyr265Cys variants had lower carboxymethylation
(p ¼ 0.001, 0.03, 0.02, 0.03, and 0.02, respectively) than
WT Ca (Figures 4A and 4B and Table 2), whereas the
p.His191Arg variant showed a trend toward increased
demethylation (p ¼ 0.095). For the p.Asp131His and
p.Asp223His variants, however, there were no significant
differences (p > 0.15). The decrease in methylation was
most pronounced for the p.Asp88Gly, p.Tyr127Cys,
and p.Tyr265Cys mutants, in which the mutated residues
are part of the catalytic center and are in close or direct
contact with the PP2A methyltransferase LCMT-1.27
The observed PP2A activity defects in these variants
(Figure 3) are in accordance with their inability to be
properly methylated, given that effective C subunit
carboxymethylation requires an active conformation of
PP2A-C.27
For the p.Phe308dup variant, the anti-demethyl anti-
bodies revealed no signal at all, as was the case for the
C tail lacking the p.Arg295* variant, suggesting that the
antibodies are probably unable to recognize this mutant
(Figure 4A). Hence, we could draw no conclusions
regarding potential methylation defects of the variant
with a 1 amino acid extension of the C tail. How-
ever, given the severe effect on activity (Figure 3), we spec-
ulate that this mutant might have impaired methylation
as well.
PPP2CA Mutations Alter PP2A Subunit Binding in a
Mutation-Specific Manner
To investigate whether the PPP2CA missense mutations
affect PP2A subunit interactions, we first assessed binding
of the HA-tagged Ca mutants to the endogenous A sub-
unit. After HA pull-down of HA-tagged Ca mutants intro-
duced in HEK293T cells, the presence of the A subunit in
the bead fractions was monitored by anti-A immunoblot-
ting. Whereas A subunit binding for the p.Gln122His,
p.Tyr127Cys, p.His191Arg, p.Asp223His, and p.Asp223Val
mutants was not obviously impaired in comparison with
that of WT Ca, structural A subunit binding was signifi-
cantly decreased for p.Asp88Gly, p.Asp131His, Tyr265Cys,
p.Arg295*, and p.Phe308dup mutants (30%–60% of WT
Ca binding) and even completely abolished for the
p.Arg214* mutant (Figures 5A–5C and Table 2). For
the latter, however, we noticed strong binding to endoge-
nous alpha 4 (Figure 5D and Table 2), a non-canonical
PP2A subunit whose binding is mutually exclusive with
the A subunit. Alpha 4 binding stabilizes the C subunit
in a latent form,24,36 which is consistent with our observa-
tion of the complete lack of phosphatase activity for
p.Arg214* as shown in our assays (Figure 3).
We next assessed binding of the Ca mutants to at least
one representative of the regulatory B55, B56, B00, and
B00 0/striatin subunit classes. To this end, N-terminally
GST-tagged B55a (encoded by PPP2R2A), B56a–B56ε
(encoded by PPP2R5A–PPP2R5E), and B0 0/PR72 (encoded
by PPP2R3A) (Figure 6A, Table 2, and Figure S1) or
N-terminally GFP-tagged B00 0/SG2NA (encoded by STRN3)
(Figure 6B and Table 2) was co-expressed with HA-tagged
WT or mutant Ca. The retrieved Ca proteins in GST pull-
downs or GFP traps were subsequently visualized by anti-
HA immunoblotting.
Whereas essentially no B-type subunit binding defects
could be identified for the p.Gln122His, p.Asp233His,
and p.Asp223Val variants in GST pull-downs (Figure 6C
and Figures S1E–S1G), a highly diverse aberrant B-type
subunit binding pattern was detected for the other mu-
tants. The p.His191Arg mutant significantly lost binding
Figure 3. Phosphatase Activity of Mutant
PP2A Ca Subunits
HA-taggedWTandmutant Ca proteins were
purified from transfected HEK293T cells by
HA pull-down, and absolute PP2A activity
was determined on the K-R-pT-I-R-R phos-
phopeptide substrate with BIOMOL Green.
Specific PP2A activities were calculated via
correction of the measured activities for
actual Ca inputs, determined by anti-HA
immunoblotting. Results represent the
average specific activity 5 SEM for a given
Camutant in relation to the specific activity
of WT Ca (set at 100% in each experiment),
as determined in at least three independent
experiments (n R 3). A one-sample t test
(compare to100%)wasused for assessing sta-
tistical significance (*p % 0.05, **p % 0.01,
***p% 0.001, ****p% 0.0001).
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Table 2. Overview of Mutation-Specific Biochemical Defects
PPP2CA
Variant
Protein
Detected
Activity
(%)
A Binding
(%)
Alpha 4
Binding Demethylation
B55a
Binding (%)
B56a
Binding (%)
B56b
Binding (%)
B56g1
Binding (%)
B56d
Binding (%)
B56ε
Binding (%)
PR72
Binding (%)
STRN3
Binding (%)
WT Ca þ 100 100 NA 100 100 100 100 100 100 100 100 100
p.Asp88Gly þ 3**** 37**** NA 1379** 0**** 17**** 20**** 88 195 41** 18** 52**
p.Gln122His þ 40*** 78 NA 183* 176 228** 177 135 285 254* 118 384*
p.Tyr127Cys þ 11**** 82 NA 1109* 108 15** 27* 33* 18** 14**** 31* 273
p.Asp131His þ 211* 48**** NA 200 185 0**** 0**** 0**** 5**** 0**** 149 296
p.His191Arg þ 26**** 102 NA 218 199 99 73 57 14**** 34 65 652*
p.Asp223Val þ 101 83 NA 243* 239 165 160 254 180 163* 479 72
p.Asp233His þ 61* 81 NA 138 129 97 105 111 105 147** 108 142
p.Tyr265Cys þ 19** 30*** NA 1046* 1**** 6*** 3**** 24* 42* 7**** 2**** 8****
p.Arg295* þ 48** 36** NA ND 0**** 0**** 0**** 0**** 18*** 0***** 0**** 235
p.Phe308dup þ 10*** 62* NA ND 15*** 64 166 69 206 198 5**** 372*
p.Gly60Val 5 ND ND NA ND ND ND ND ND ND ND ND ND
p.Gln125*  ND ND ND ND ND ND ND ND ND ND ND ND
p.Phe146fs  ND ND ND ND ND ND ND ND ND ND ND ND
p.Arg214* þ 0**** 0**** yes ND 0**** 0**** 0**** 0**** 0**** 0**** 0**** NA
Abbreviations are as follows: ND, not determinable; NA, not analyzed; þ, present; 5, detected at very low level; , not detected; *p% 0.05; *p % 0.01; ***p % 0.001; ****p % 0.0001.
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to only B56d (Figure 6C and Figure S1A). The p.Arg295*
mutant lost binding to all B55, B56, and B0 0 subunits tested,
except for B56d, to which binding was, although signifi-
cantly decreased, still slightly retained (Figure 6C and
Figure S1A). The p.Asp88Gly and p.Tyr265Cys variants
showed a similar pattern of severe binding defects to all
B55, B56, and B0 0 subunits but a higher overall binding
level to the B56-type subunits than p.Arg295*, particularly
to the B56g and B56d subunits (Figure 6C and Figures S1C
and S1F). The p.Asp131His variant specifically lost binding
to all B56 subunits, whereas binding to B55 and B0 0 sub-
units was entirely preserved (Figure 6C and Figure S1D).
On the contrary, mutant p.Phe308dup completely lost
binding to B00/PR72, showed decreased binding to B55a,
and retained binding to all B56 isoforms (Figure 6C and
Figure S1B). For the p.Tyr127Cys variant, binding was
diminished for all B56 and B0 0 subunits tested and intact
for B55a (Figures 6A and 6C). As expected from its com-
plete lack of A subunit binding, p.Arg214* failed to bind
any B-type subunit tested (data not shown).
Interestingly, the majority of Ca mutants retained
binding to the B00 0/striatin subunit STRN3, and for the
p.Gln122His, p.His191Arg, and p.Phe308dup variants,
this interaction was even significantly enhanced (Figures
6B and 6C). This observation was also previously made
for ID-associated mutations in PPP2R1A, encoding the Aa
subunit.38 However, for the p.Asp88Gly and p.Tyr265Cys
mutants, STRN3 binding was diminished or completely
abolished (Figures 6B and 6C).
Discussion
PP2A is an important holoenzyme for which broad
substrate specificity is orchestrated by different subunit
compositions: in particular, the B subunits play a pivotal
role in determining substrate specificity, regulation, and
hence physiologic functions of the different PP2A com-
plexes. With this broad specificity, PP2A is involved in
diverse cellular processes, and variants in either of these
subunits could therefore cause disease. Here, we report
the identification of a syndrome caused by de novo muta-
tions in PPP2CA and characterized by mild to profound
ID andDD, behavioral problems, variable types of epilepsy,
hypotonia, abnormal head circumference, and brain ab-
normalities such as corpus callosum abnormalities and
ventriculomegaly. Some individuals had mild dysmorphic
features, but a recognizable facial gestalt could not be
observed.
Mutations in several other PP2A-subunit-encoding
genes have been reported before and result in an ID and
DD phenotype. Interestingly, albeit not unsurprisingly,
B
A
Figure 4. Carboxyterminal Methylation of Mutant PP2A Ca Subunits
(A) HA-taggedWTandmutant Ca proteins were isolated from transfected HEK293T cells by HA pull-down. PP2A C subunit methylation
was subsequently assessed by immunoblotting with a demethyl-specific anti-C monoclonal antibody. Immunoblot data from a single
representative experiment are shown (n R 4).
(B) The average ratios of the quantified demethyl-specific signals over the quantified anti-HA signals 5 SEM are displayed (n R 4)
in relation to those of WT Ca (set at 100%). A one-sample t test (compare to 100%) was used for assessing statistical significance
(*p % 0.05, **p% 0.01).
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individuals with a de novo mutation in PPP2CA showed a
phenotypic resemblance to those individuals harboring
an ID- and DD-related pathogenic variant in other PP2A
subunits10–12 (Table S2). This overlap consisted of ID,
DD, and hypotonia (in all individuals with PPP2R1A and
PPP2R5D mutations), epilepsy and ventriculomegaly (in
some individuals with PPP2R1A and PPP2R5Dmutations),
ASD (in some individuals with a PPP2R5D mutation),
corpus callosum agenesis (in all individuals with a
PPP2R1A mutation and some individuals with a PPP2R5D
mutation), and congenital heart disease (ventricular and
atrial septal defects in two individuals with a mutation in
PPP2R5D). Severe speech delay was also noted in multiple
individuals and for multiple subunits, which might be
partially related to the severity of ID but was more severe
than expected in several individuals. A noticeable differ-
ence from mutations in other subunits is the absence of
overgrowth, which was reported for individuals with path-
ogenic mutations in PPP2R5B, PPP2R5C, and PPP2R5D11
but was observed in only one individual with a de novo
mutation in PPP2CA. In addition, although two individ-
uals were macrocephalic, five other individuals had
microcephaly, a phenotype also reported for cases of
PPP2R1A mutations.10 Recently, brain-specific Ppp2ca
knockout was reported to result in mice with obvious
morphological and behavioral abnormalities, including
microcephaly, cortical neuronal atrophy, plastic synapse
deficits, and learning and memory impairments at an early
postnatal stage.39 These features were also partly observed
in individuals with de novo mutations in PPP2CA, and
although the phenotypes of the heterozygous mice (if
any) were not further documented, these mice could be
an excellent in vivo model for further studies. Likewise,
congenital heart defects, specifically affecting septum
Figure 5. Binding of Mutant PP2A Ca Subunits to the A Subunit
(A) A subunit binding. HA-tagged WT and mutant Ca proteins were purified from transfected HEK293T cells by HA pull-down, and the
presence of endogenous A subunit in the complexes was determined by anti-A immunoblotting. Abbreviated amino acid changes are
as follows: H191R, p.His191Arg; R295*, p.Arg295*; F308dup, p.Phe308dup; Y127C, p.Tyr127Cys; D131H, p.Asp131His; D223V,
p.Asp223Val; Y265C, p.Tyr265Cys; D88G, p.Asp88Gly; Q122H, p.Gln122His; and D223H, p.Asp223His.
(B) Same experimental setup as in (A), but in this case, HA-agarose-bound proteins were eluted from the beads with an excess of free
HA-tagged peptide before anti-A immunoblotting of the eluates. This setup was necessary for enabling unambiguous visualization of
HA-tagged p.Arg214*, which co-migrated with immunoglobulin light chains at approximately 25 kDa.
(C) Quantified values of A subunit binding. Results represent the average value5 SEM of the ratios of the quantified anti-A signal to the
quantified anti-HA signal for a given Camutant in relation to those ofWT Ca (set at 100% in each experiment), as determined in at least
four independent experiments (nR 4). A one-sample t test (compare to 100%) was used for assessing statistical significance (*p% 0.05,
**p% 0.01, ***p% 0.001, ****p% 0.0001).
(D) Alpha 4 subunit binding. HA-taggedWTand p.Arg214*mutant Ca proteins were purified from transfected HEK293Tcells by HA pull-
down and eluted from the beads by excess HA peptide, and eluates were subjected to immunoblotting with anti-alpha 4 monoclonal
antibodies for the detection of binding of endogenous alpha 4.
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Figure 6. Binding of Mutant PP2A Ca Subunits to B-type Subunits
(A) GST-tagged B-type subunits were co-expressedwithHA-taggedWTormutant p.Tyr127Cys Ca protein in HEK293Tcells. The presence
of the PP2A C variant was subsequently assessed in GST pull-downs by anti-HA immunoblotting. Representative blots of similar assays
with other Ca variants can be found in Figure S1.
(B) GFP-tagged B0 0 0/STRN3 or GFP alone was co-expressed with HA-tagged WT or mutant Ca proteins in HEK293T cells. The presence of
Ca variants was subsequently assessed in GFP traps by anti-HA immunoblotting.
(legend continued on next page)
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formation, have been reported in B56g-knockout mice
and in transgenic mice specifically overexpressing a
dominant-negative mutant of Aa in (cardiac) muscle.40,41
All functionally characterized and clinically described
variants in subunits of PP2A so far and our data on PPP2CA
variants collectively seem to constitute overlapping
syndromic forms of ID involving more than one gene
but functionally converging to PP2A deficiency, and they
could therefore be redefined as ‘‘PP2A-related neurodeve-
lopmental syndrome.’’
Notably, for most individuals, WES was used to identify
the PPP2CA mutation, so other rare (de novo) mutations
were also identified in 6 of 16 individuals. Whereas these
most likely reflect the background per-generation de novo
mutation rate, a contribution of these de novo variants to
the individuals’ phenotypes cannot be excluded. Similarly,
involvement of the partial CDKL3 deletion to the pheno-
type of individual 11 cannot be ruled out given that
a balanced CDKL3-disrupting translocation leading to
decreased expression of CDKL3 has previously been re-
ported in an individual with mild ID.42 To collect further
insight into the clinical spectrum, we established a website
on the Human Disease Genes platform for the collection of
clinical data (see Web Resources).
By far most reported individuals with PP2A variants so
far harbor de novo mutations in PPP2R5D, encoding the
regulatory B56d subunit.10–12 Biochemical characteriza-
tion has revealed that the vast majority of these variants
show decreased binding to the A and C subunits, hinting
at a dominant-negative mode of action.10 Similarly, char-
acterization of de novo mutations in PPP2R1A, encoding
the scaffolding Aa subunit,10 has identified defective bind-
ing of nearly all B-type subunits, except for B56d. Yet for
the latter variants, the Aa-B56d complexes have proved
catalytically impaired,10 potentially because of increased
recruitment of a cellular PP2A inhibitor, TIPRL1.38 Our
functional assays, focusing on the functional defects
following PPP2CA mutations, showed similar defects—
that is, our binding assays suggested that some Ca variants,
although catalytically impaired, were indeed still able to
form trimeric complexes with specific B-type subunits,
providing a mechanistic basis for their potential domi-
nant-negative mode of action. Clearly, such a dominant-
negative mechanism would affect only a set of specific
holoenzymes rather than the whole PP2A spectrum.
This scenario is most likely the case for the p.Asp88Gly,
p.Tyr265Cys, p.Arg295*, and p.Phe308dup variants, which
all showed significantly decreased catalytic activity but
still retained binding to at least B56d. Moreover, the
p.Asp88Gly and p.Arg295* variants occurred in individuals
with severe ID, and the p.Phe308dup variant caused mod-
erate ID—all in line with a potential dominant-negative
effect on PP2A-B56d complexes (for p.Arg295*), on PP2A-
B56g and B56d complexes (for p.Asp88Gly), or on all
PP2A-B56 complexes (for p.Phe308dup). In contrast, the
individual with the p.Tyr265Cys variant had mild ID
(with comorbid epilepsy, hypotonia, brain MRI abnormal-
ities, ASD, and ADHD), suggesting that in this case, the
50% retained binding to B56d might not be causally
involved, but rather the significantly decreased binding
to all B-type subunits is the most important determinant,
bringing us into a scenario of haploinsufficiency in this
particular individual. Likewise, haploinsufficiency would
be the proposed mechanism for the partial PPP2CA
deletion and the p.Gln125*, p.Phe146Leufs*29, and
p.Arg214* variants, all of which lead to complete null al-
leles (due to the lack of expression in the first three cases
or expression of a completely dysfunctional variant in
the last case), as well as for the very poorly expressed
p.Gly60Val variant. All of these individuals had mild ID
often accompanied by severe epilepsy. Notably, the re-
maining 50% of WT Ca in those five individuals might
no longer be sufficient to assemble all PP2A holoenzymes,
as previously suggested for specific cancer-associated
Aa (PPP2R1A) mutants43,44 and haploinsufficiency of
PPP2R4, encoding the PP2A activator PTPA.45 Upon loss
of one functional allele for those two genes, selective
PP2A dysfunctions were observed for B56-subunit-contain-
ing complexes, specifically B56g, B56d, and B56ε (whereas
B55 complexes remained fully functional), as a result of a
competition mechanism between B subunits for binding
the remaining WTAa subunit or fully activated C subunit.
In other words, both PPP2R1A and PPP2R4 haploinsuffi-
ciency caused a selective PP2A-B56 defect. In this respect,
it is interesting to point out that three B-type-subunit-
encoding genes hitherto reported to be involved in the eti-
ology of ID and DD all encode subunits of the B56 family
(d, g, and b isoforms).10,11 Thus, in those PPP2CA cases
where we suspect haploinsufficiency as the pathological
mechanism, the eventual PP2A dysfunctions could be
highly similar and mainly affect B56-type holoenzymes.
On the basis of our biochemical assays, such a selective
B56 defect also seems to be the case for the catalytically
competent p.Asp131His variant, which retained binding
to all B-type subunits tested, except for all B56 isoforms.
The p.Tyr127Cys variant also lost binding to all B56
subunits, as well as to B00/PR72. However, in this case, the
catalytic activity and methylation of this variant were
also significantly impaired, suggesting that a dominant-
negative mechanism toward PP2A-B55 and PP2A-STRN
(C) Quantified values of C subunit binding. Results represent the average value5 SEM of the ratios of the quantified anti-HA signal to
the quantified anti-GSTor anti-GFP (in the case of STRN3) signal for a given Camutant in relation to those ofWTCa (set at 100% in each
experiment, dotted line), as determined in at least three independent binding experiments (n R 3). A one-sample t test (compare to
100%) was used for assessing statistical significance (*p% 0.05, **p% 0.01, ***p% 0.001, ****p% 0.0001).
Abbreviated amino acid changes are as follows: H191R, p.His191Arg; R295*, p.Arg295*; F308dup, p.Phe308dup; Y265C, p.Tyr265Cys;
Y127C, p.Tyr127Cys; D131H, p.Asp131His; D223V, p.Asp223Val; D88G, p.Asp88Gly; Q122H, p.Gln122His; and D223H, p.Asp223His.
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complexes might additionally be in place—further ex-
plaining the severe ID in this individual. Despite a rela-
tively large number of available PPP2CA-knockout mouse
models, heterozygous Ca-null mice have unfortunately
never been phenotypically or biochemically examined.46
In any case, our data provide evidence that PPP2CA is a
haploinsufficient gene in humans.
The only recurrent PPP2CA variant in our cohort,
c.572A>G (p.His191Arg), showed a (non-significant) in-
crease in demethylation signal (218%; p ¼ 0.095) and a
decrease in activity (48%; p ¼ 0.001), whereas no changes
in A or B subunit interaction could be detected, except for
B56d (for which binding was decreased) and for B0 0 0/
STRN3 (for which binding was increased). Both individ-
uals with this variant had a mild ID phenotype and fe-
ver-related seizures. Structural studies suggested that the
His191 residue is important in PP2A-C’s interaction with
alpha 424 and thereby induces displacement of the
catalytic center and subsequent reduction in activity.28
Additionally, in a yeast model, the p.His191Arg variant
was incapable of exhibiting a dominant-negative effect
on WT human PP2A Ca in a growth assay.47 This could
indicate a potential haploinsufficient mechanism of
the p.His191Arg variant, which mainly affects B56d-
containing holoenzymes. The biochemical profile of the
p.Gln122His variant appeared very similar to that of
p.His191Arg, except for the retained binding to B56d in
p.Gln122His. Both affected residues are indeed two of
four residues that are directly involved in binding the
hydrophobic part of pharmacologic PP2A inhibitors, oka-
daic acid, and microcystin.25
Finally, the p.Asp223His and p.Asp223Val variants did
not seem to have a significant impact on PP2A assembly
and function in any of our assays tested, except for a
slight increase in B56ε binding (150%), a slight decrease
in activity (for p.Asp223His), and a light increase in de-
methylation signal (for p.Asp223Val). The latter might
suggest that the clinical phenotype might be milder,
but this was not the case for individual 16 (p.Asp223His),
who had severe ID. Also, although the other individual
(individual 7, p.Asp223Val) initially had a normal IQ,
she showed speech delay and ASD and additionally
developed progressive cognitive dysfunction after a psy-
chotic episode at the age of 17 years. In the absence of
a clear pathogenic effect for these two variants in the
majority of our biochemical assays tested, it could be
speculated that another (yet unidentified) genetic variant
contributes to the disease manifestation of individuals 7
and 16.
Many of the observed biochemical defects in specific
Ca variants can be rationalized by structural data from
crystallographic studies or are sustained by previously
reported biochemical and functional studies of PP2A
C mutants in yeast. The variants affecting Asp88 and two
tyrosine residues in the catalytic center—p.Tyr127Cys
and p.Tyr265Cys—both induced a drastic decrease in
methylation and activity. Most likely the variants induce
an inactive Ca conformation, which subsequently pre-
vents methylation. In yeast, a p.Tyr127Asn variant was
also identified as LoF because it could not rescue the
growth defect of a PP2A-C deletion strain.47 For the
p.Asp131His, p.His191Arg, and p.Asp223His variants,
the effects were less clear, although there might have
been a trend toward slightly decreased methylation for
the pHis191Arg variant. On the other hand, a slight but
significant decrease in methylation of the p.Asp223Val
mutant was detected, whereas the p.Asp223His variant,
affected in the same residue, behaved like the WT. Besides
a charge difference between the mutated amino acids, a
straightforward structural explanation for this observation
could not be found. A similar increase in demethylated
signal could be observed for the p.Gln122His variant.
Although it’s impossible to measure with the available an-
tibodies, we expect methylation of p.Phe308dup to be
diminished as well. On the basis of the ‘‘deep and narrow
cleft’’ conformation of the active center of the PP2A meth-
yltransferase LCMT-1 and the fact that several residues in
the C tail need to form stabilizing contacts with the
LCMT-1 active-site residues for efficient methylation to
occur, a tail that is 1 amino acid too long might no longer
fit in and thus no longer be modified.
The c.640 C>T (p.Arg214*) nonsense mutation is
located in PPP2CA exon 5. Migueleti et al. reported on
the existence of a shorter PPP2CA mRNA, in which
this specific exon can be skipped, in peripheral-blood
mononuclear cells under specific growth conditions
(serum exhaustion), and this mRNA resulted in a slightly
shorter Ca isoform.48 Although we do not favor potential
exon 5 skipping in the c.640 C>T (p.Arg214*) variant
given our data and observed molecular weight of the pro-
tein detected, it is remarkable that this shorter isoform
was reported as catalytically inactive without any binding
to the scaffolding A subunit and increased binding to
alpha 4, very much like our data for the truncated
p.Arg214* protein. This would suggest an important role
for exon-5-encoded amino acids in A subunit binding.
Tang et al. further demonstrated that expression of the
shorter Ca isoform had no effect on the expression or
the modification of the longer Ca variant, thus disfavoring
a dominant-negative effect of the shorter variant.49
In summary, we have identified 16 individuals with a
syndrome characterized by ID, DD, hypotonia, epilepsy,
behavioral problems, and structural abnormalities of the
brain and with a de novo mutation in or partial deletion
of PPP2CA, encoding one of the catalytic subunits of
PP2A. Functional characterization of all the Ca variants
in HEK293T cells showed a diverse spectrum of biochem-
ical distortions that were unique to each variant but al-
ways justified the conclusion of a functional loss and
affected at least the functionality of the PP2A-B56d com-
plexes. Only for both p.Asp223 missense variants, our
results failed to reveal a major biochemical defect. Our
data further expand the repertoire of PP2A subunits
involved in the etiology of ID and DD and underscore
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the importance of PP2A in neurodevelopmental processes
and brain function. Hence, we propose that de novo muta-
tions in PPP2CA, PPP2R1A, and PPP2R5D constitute a
spectrum of overlapping ID syndromes characterized by
mild to severe phenotypes and functional convergence
by severe PP2A dysfunction, and we propose that these
collectively be called ‘‘PP2A-related neurodevelopmental
disorders.’’
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